Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Shares of Incyte (Nasdaq: INCY) were gapping down Monday morning with an open price 12.2% lower than Friday's closing price. The stock closed at $24.84 Friday and opened today's trading at $21.82.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
The average volume for Incyte has been 1.6 million shares per day over the past 30 days. Incyte has a market cap of $3.34 billion and is part of the health care sector and drugs industry. Shares are up 49.5% year to date as of the close of trading on Friday. Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. TheStreet Ratings rates Incyte as a sell. Among the areas we feel are negative, one of the most important has been poor profit margins. You can view the full Incyte Ratings Report. Get more investment ideas from our investment research center. It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.